I earned my PhD degree in Biomedical Sciences at the University of Debrecen, Hungary in 2008. During my studies in the Retroviral Biochemistry Lab, I was interested in designing of dominant negative HIV-1 protease inhibitors and testing their activity using a novel high-throughput microtiter plate fluorescent assay. Between 2006 and 2008 I was also a researcher in the InnoTears Ltd., where I was working on the recombinant plasminogen activator inhibitor-2 fusion peptide production and usage in corneal ulcer treatment as an eye-drop. This idea was patented in 2009.

From February 2009 to January 2012 I worked at the SUNY Upstate Medical University in Syracuse, NY, USA as a postdoctoral fellow. I was focusing on the biochemistry of transaldolase and HRES1/Rab4 for better understanding of the pathophysiology of Systemic Lupus Erythematosus. Furthermore I was involved in two clinical trials as a subinvestigator. The purpose of the studies is to determine the therapeutic efficacy and mechanism of action of Rapamune in patients with SLE and the impact of an optimal N-acetylcysteine dose on disease activity.

Between January 2012 and July 2016 I worked at the University of Hawaii Cancer Center in Honolulu, HI, USA as a postdoctoral researcher. I was a member of a drug discovery group where I was screening and characterizing natural products for drug candidate development against cancer.

From August 2016 to August 2019 I was a Staff Scientist at Baylor College of Medicine Center for Drug Discovery in Houston, TX, USA. I used  DEL technology to identify promising drug candidates for many human diseases.

Since September 2019 I have been working at Arvinas in New Haven, CT, USA, first as a Research Investigator then in December 2022, I was promoted to Senior Research Investigator. My current work is to identify promising drug candidates for a wide variety of human disorders using DNA-encoded library technology (DEL).

My detailed Curriculum Vitae can be seen here.